First report of Successful Clearance of Hepatitis B and D Coinfection With Tenofovir Monotherapy

Hepatology

Volumn 62, Issue 1, 2015, Pages 317-318

  James, Gary ^a   Sidhu, Prabhjot ^a   Raza, Mohammad ^b  

^a DONCASTER ROYAL INFIRMARY   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON; PROPRANOLOL; TENOFOVIR; ADENINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL THERAPY; ARTICLE; DELTA AGENT HEPATITIS; DISEASE CLEARANCE; GASTROINTESTINAL ENDOSCOPY; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERSPLENISM; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MIXED INFECTION; MONOTHERAPY; PORTAL HYPERTENSION; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTE COUNT; VIRUS REPLICATION; ADULT; ANALOGS AND DERIVATIVES; CASE REPORT; COMPLICATION; HEPATITIS D; MALE;

ADENINE; ADULT; COINFECTION; HEPATITIS B; HEPATITIS D; HUMANS; MALE; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84937191139     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27446     Document Type: Article

References (6)

1. Sheldon J, Ramos B, Toro C, Rios P, Martinez-Alarcon J, Bottecchia M, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther 2008;13:97-102.
2. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010;7:31-40.
3. Manesis EK, Vourli G, Dalekos G, Vasiliadis T, Manolaki M, Hounta A, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13 year prospective study. J Hepatol 2013;59:949-956.
4. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011;378:73-85.
5. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degerteken H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-331.
6. Wedemeyer H, Yurdaydin C, Ernst S, Caruntu FA, Curescu MG, Yalcin K, et al., HIDIT-2 Study Group. Prolonged therapy of hepatitis delta for 96 weeks with pegylated-interferon-α-2a plus tenofovir or placebo does not prevent HDV RNA relapse after treatment: the HIDIT-2 study. J Hepatol 2014;60(Supp):S2-S3.